This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lizée, G. Articles by Hwu, P. Search for Related Content PubMed PubMed Citation Articles by Lizée, G. Articles by Hwu, P. Related Collections Tumor Biology: Inflammation and Immune Escape Cancer Immunology Cancer Immunology: Immunotherapy

Less Yin, More Yang: Confronting the Barriers to Cancer Immunotherapy

Authors' Affiliation: Department of Melanoma Medical Oncology, M. D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Patrick Hwu or Gregory Lizée, Department of Melanoma Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 430, Houston, TX 77030. Phone: 713-792-2921; Fax: 713-745-1046; E-mail: phwu{at}mdanderson.org or glizee{at}mdanderson.org.

Abstract

Clinical trials involving T cell–based immunotherapy for the treatment of human cancer have shown limited degrees of success. In cancer vaccine trials conducted at multiple centers worldwide, immunization has often resulted in the robust elicitation of T cells that specifically recognize antigens expressed on the surface of tumor cells. However, to date, objective clinical responses resulting from these approaches have remained relatively rare. By contrast, adoptive transfer of laboratory-expanded T cells into patients has had more success, producing impressive clinical regressions in a subset of advanced metastatic melanoma patients. The failure of activated T cells to consistently induce clinical responses in many other patients has pushed us toward a deeper understanding of natural immunoregulatory mechanisms that are directly responsible for diminishing tumor-specific T-cell activation, migration, and effector function in vivo. Such immunosuppressive factors likely evolved to prevent autoimmunity, but are frequently co-opted by tumors to evade tumor-specific immune responses. With this knowledge, it now becomes imperative to develop specific clinical interventions capable of eliminating tumor-specific immunosuppression, with the goal of shifting the balance to favor effector T-cell function and tumor cell killing.

This article has been cited by other articles:

				G. C. Prendergast Breaking Immune Suppression in Cancer: The Emerging Revolution in Immunotherapy Cancer Reviews Online Content, October 1, 2007; 2007(7): 13 - 14. [Full Text] [PDF]

				S. H. Wrzesinski, Y. Y. Wan, and R. A. Flavell Transforming Growth Factor-{beta} and the Immune Response: Implications for Anticancer Therapy Clin. Cancer Res., September 15, 2007; 13(18): 5262 - 5270. [Abstract] [Full Text] [PDF]